What this is
- How it works
- How it works isn't classified yet
- Tested for
- Knee Osteoarthritis (Knee OA)
- Main trialPhase 2
- “1. Study Objective To Explore the Efficacy and Evaluate the Safety of Vutiglabridin in Knee Osteoarthritis Patients 2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in Knee Osteoarthritis Patients 3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based…”In the company’s words, NCT06845553 on ClinicalTrials.gov
- Other names
- HSG4112
Other drugs for Knee Osteoarthritis (Knee OA)
- JointstemR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Jul 2026 | A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients | |
| Phase 2Completed | 31 Dec 2022 | A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients | |
| Phase 2Completed | 16 Dec 2025 | A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients | |
| Phase 1Completed | 10 Feb 2021 | A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112 | |
| Phase 1Completed | 24 May 2021 | A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112 | |
| Phase 1Completed | 20 Jan 2022 | A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112 | |
| Phase 1Completed | 12 Dec 2022 | A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026